[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fifth Affiliated Hospital, Sun Yat-Sen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":260},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,75,96,118,137,163,190,213,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100520762","phase-1-thiotepa-cyclophosphamide-clarithromycin-and-cytarabine-100520762",false,"NCT06060782","Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine","Clinical Study on the Efficacy and Safety of Auto-HSCT in Adult Patients with Burkitt Lymphoma, Lymphoblastic Lymphoma, and Acute Lymphoblastic Leukemia Who Received TCCA Conditioning Regimen","TCCA","Inclusion Criteria:\n\n* 1\\. Voluntarily sign the informed consent form, which must be signed by the patient himself.\n\n  2\\. ALL patients confirmed by bone marrow cell morphology, immunology, and genetics; 3. PH+ALL patients who achieve s3CMR (definition: achieve molecular biological remission in the early stage of initial treatment (within 3 months) and maintain remission); 4. Ph-B-ALL patients who have reached MRD- after 3 courses of chemotherapy and continue to be MRD-; adult patients with Burkitt lymphoma and lymphoblastic lymphoma confirmed by histopathology and molecular genetics; 5. Adult patients with Burkitt lymphoma and lymphoblastoma, if the bone marrow is not involved, can achieve PR or above after induction; if the bone marrow is involved at the time of initial diagnosis, 3 courses of chemotherapy are required to reach MRD- and continue to be MRD-.\n\n  6\\. Patients receiving autologous hematopoietic stem cell transplantation (auto-HSCT); 7. Age ≥18 years and ≤65 years old, male or female; 8. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2;\n\nExclusion Criteria:\n\n* 1\\. Have a history of cancer and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer, basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN), or prostate epithelium Internal carcinogenesis (PIN); 2. Known to be serologically positive for HIV, active hepatitis B, active hepatitis C virus or syphilis; 3. Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring; 4. Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 5. Received hematopoietic stem cell transplantation within the past 1 year; 6. Active heart disease, defined as one or more of the following:\n\n  1. Have a history of uncontrolled or symptomatic angina;\n  2. Myocardial infarction less than 6 months from study enrollment;\n  3. Have a history of arrhythmia that requires drug treatment or has severe clinical symptoms;\n  4. Uncontrolled or symptomatic congestive heart failure (\\>NYHA class 2);\n  5. The ejection fraction is lower than the lower limit of the normal range. 7. Patients who meet the following criteria:\n\n  \u003C!-- -->\n\n  1. Major surgery (except diagnostic surgery) is planned within 4 weeks before enrollment or during the study period, or the surgical wound has not fully healed before enrollment;\n  2. Those who have received (attenuated) live vaccines within 4 weeks before enrollment;\n  3. Patients with suspected active or latent tuberculosis;\n  4. Participate in other clinical trials one month before enrollment 8. Those who the researcher believes are not suitable for enrollment","ALL","18 Years","65 Years",{"count":21,"type":22},28,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study is an observational study on the efficacy and safety of auto-HSCT in adult patients with Burkitt lymphoma, lymphoblastic lymphoma, and acute lymphoblastic leukemia who received TCCA conditioning regimen. The study plans to include 28 patients who received the TCCA regimen for pre-transplantation pretreatment before auto-HSCT. Maintenance treatment will be carried out after transplantation for 1 year to observe the efficacy and safety.",[28,29,30],"Burkitt Lymphoma","Lymphoblastic Lymphoma, Adult","Acute Lymphoblastic Leukemia, Adult",[32,33,34,35,36],"Thiotepa","Cyclophosphamide","Cladribine","Cytarabine","conditioning regimen","RECRUITING","2025-03-04",{"date":40,"type":41},"2025-03-06","ACTUAL",{"date":43,"type":41},"2024-03-06",{"date":45,"type":22},"2026-12-31",{"name":47,"class":48},"Fifth Affiliated Hospital, Sun Yat-Sen University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100556432","building-a-traditional-chinese-medicine-clinical-diagnosis-and-treatment-database-100556432","NCT06525025","Building a Traditional Chinese Medicine Clinical Diagnosis and Treatment Database","Building a Traditional Chinese Medicine Clinical Diagnosis and Treatment Database: A Prospective Multicenter Cross-Sectional Study","Inclusion Criteria:\n\n* People who come to the hospital for physical examination and medical treatment；\n* Participants voluntarily participate in the study.\n\nExclusion Criteria:\n\n* Subjects with difficulty in tongue extension, communication, etc. who cannot cooperate with data collection；\n* The researchers determined that there were other factors that may have forced the subjects to terminate the study.",true,"85 Years",{"count":60,"type":22},80000,"OBSERVATIONAL","Collecting Traditional Chinese Medicine (TCM) clinical diagnosis and treatment data, including doctor-patient dialogues, tongue diagnosis, facial diagnosis, and TCM constitution information, to construct databases for tongue diagnosis, TCM constitution, and doctor-patient dialogues. Based on artificial intelligence technology, engage in research related to the standardization and intelligentization of TCM.",[64,65],"Medicine, Chinese Traditional","Artificial Intelligence","NOT_YET_RECRUITING","2024-07-24",{"date":69,"type":41},"2024-07-29",{"date":71,"type":22},"2024-08-01",{"date":73,"type":22},"2026-08-15",{"name":47,"class":48},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":49},"100554021","study-on-the-correlation-between-treg-immune-cells-on-the-muscle-content-and-cognitive-functions-of-the-elderly-100554021","NCT06493669","Study on the Correlation Between Treg Immune Cells on the Muscle Content and Cognitive Functions of the Elderly","Inclusion Criteria:\n\n\\- aged 40-90 years old\n\nExclusion Criteria:\n\n\\- previous diagnosis of dementia (including Alzheimer's disease, Lewy body dementia, Parkinson's disease, or other dementias) were excluded.","40 Years","90 Years",{"count":84,"type":22},100,"In order to explore the impact of the level of the elderly Treg immune cells and the effects of different fat distribution and muscle content, the impact of the level of Treg immune cells on cognitive functions is explored. The correlation between visceral fat content, subcutaneous fat content and cognitive function.",[87],"Cognitive Disorder Patients and Cognitive Assessment","2024-07-07",{"date":90,"type":41},"2024-07-10",{"date":92,"type":41},"2023-05-01",{"date":94,"type":22},"2024-12-31",{"name":47,"class":48},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":49},"100533033","phase-2-the-efficacy-and-safety-of-low-dose-radiotherapy-combined-with-sintilimab-and-temozolomide-in-recurrent-glioblastoma-100533033","NCT06220552","The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma","Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma: A Single-arm, Prospective Phase II Clinical Study","Inclusion Criteria:\n\n1. Histologically confirmed glioblastoma, radiographically or pathologically diagnosed recurrence.\n2. Aged ≥ 18 years.\n3. ≥12 weeks after postoperative radiotherapy.\n4. Karnofsky performance status (KPS) ≥ 60.\n5. Expected survival \\> 3 months.\n6. Adequate organ function, based on meeting all of the following criteria (no blood components and cytologic growth factors were received within 14 days prior to the test):\n\n   1. Hemoglobin ≥ 90 g\u002FL; absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; and platelet count ≥ 100 × 10\\^9\u002FL;\n   2. Serum albumin ≥ 28 g\u002FL;\n   3. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN;\n   4. Serum creatinine ≤ 1.5 × ULN;\n   5. Activated partial clotting enzyme time and international standardized ratio (INR) ≤ 1.5 × ULN (Patients on stable doses of anticoagulant therapy such as low molecular weight heparin or warfarin with INR within the expected treatment range of anticoagulants can be screened ).\n   6. Thyroid stimulating hormone ≤ ULN; If abnormal, T3 and T4 levels should be examined, and if T3 and T4 levels are normal, they can be screened.\n7. Subjects voluntarily join the study and sign an informed consent form, with good compliance.\n\nExclusion Criteria:\n\n1. Treatment with a dose of prednisone \\> 10mg \u002Fd or equivalent dose of corticosteroids is required.\n2. There exist other uncontrolled central nervous system diseases unrelated to cancer.\n3. A history of other malignant tumors within the previous 5 years or at the time of enrollment, except for cured skin basal cell carcinoma and cervical in situ cancer, as well as thyroid papilloma.\n4. Uncontrolled cardiac clinical symptoms or diseases, such as New York Heart Association (NYHA) class II or above heart failure, unstable angina pectoris, myocardial infarction within 1 year, patients with clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention.\n5. Serious infections, such as severe pneumonia, bacteremia, and infection comorbidities requiring hospitalization, occurred within 4 weeks.\n6. Active autoimmune diseases, such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; It does not include patients with vitiligo or childhood asthma\u002Fallergies that have healed and require no intervention as adults.\n7. A history of immunodeficiency, including HIV-positive status or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and bone marrow transplantation.\n8. Patients with active tuberculosis infection found by history or CT examination, or patients with active tuberculosis infection history within 1 year prior to enrollment, or patients with active tuberculosis infection history before 1 year without formal treatment.\n9. Active hepatitis B (HBV DNA ≥ 2,000 IU\u002FmL or 10,000 copies\u002FmL) or hepatitis C (positive HCV antibody test and HCV RNA above the lower limit of detection).\n10. Known history of psychotropic drug abuse, alcoholism and drug use.\n11. Not suitable for inclusion, as judged by the investigator.",{"count":104,"type":22},20,[106],"PHASE2","This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of low-dose radiotherapy combined with programmed death 1 (PD-1) inhibitor (sintilimab) and temozolomide in recurrent glioblastoma. The eligible patients are scheduled to administered sintilimab 200mg D1 Q3W temozolomide 50mg\u002Fm2 QD and radiotherapy 1Gy\u002F1F D1\u002FD2\u002FD8\u002FD15 Q3W for 4-6 cycles, then sintilimab for maintenance. The overall primary study hypothesis is that the combination regimen of low-dose radiotherapy, sintilimab and temozolomide is safe and feasible in the treatment of recurrent glioblastoma.",[109],"Recurrent Glioblastoma","2024-01-13",{"date":112,"type":41},"2024-01-24",{"date":114,"type":41},"2023-12-27",{"date":116,"type":22},"2027-12-30",{"name":47,"class":48},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":49},"100520761","study-on-the-quantitative-assessment-of-the-risk-of-hepatocellular-carcinoma-in-patients-with-chronic-liver-disease-using-multi-parameter-magnetic-resonance-imaging-100520761","NCT06060769","Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging","Inclusion Criteria:\n\n* 1\\. Aged over 18 years old; 2. Liver function Child-Pugh classification A or B; 3. Patients with chronic liver disease who meet the diagnostic criteria for high-risk groups of liver cancer in the \"Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)\"; 4. Equipped with Gd-EOB-DTPA enhanced MRI scan images, including T1 mapping, T2 mapping, T2\\* mapping, T1ρ and other sequences; 5. With 5-year follow-up data.\n\nExclusion Criteria:\n\n* 1\\. Patients who are unable to undergo MRI scanning due to claustrophobia, abnormal renal function, etc.; 2. Patients who have undergone liver surgery in the past; 3. Patients with major diseases such as heart failure and tumors.",{"count":125,"type":22},1200,"Quantitative MRI scanning parameters such as T1 mapping, T2 mapping, T1ρ, and elastography are used, combined with clinical and laboratory indicators, to predict the risk of liver cancer in patients with cirrhosis.",[128],"Cirrhosis； Tumor","2023-09-25",{"date":131,"type":41},"2023-09-29",{"date":133,"type":41},"2023-09-01",{"date":135,"type":22},"2029-01-31",{"name":47,"class":48},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":49},"100504937","the-efficacy-and-safety-of-de-escalated-postoperative-radiotherapy-in-locally-advanced-hnscc-with-pcrmpr-100504937","NCT05854823","The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR\u002FMPR","De-escalation of Postoperative Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma With Pathological Complete Response\u002FMajor Pathological Response: A Single-arm, Prospective Phase II Clinical Study","Inclusion Criteria:\n\n1. Untreated, histologically confirmed head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx or larynx), staging T3-4N0M0 or T1-4N1-3M0, III-IVB, according to the eighth edition of the AJCC staging system; within 6 weeks after receiving neoadjuvant therapy and radical surgery.\n2. Pathological evaluation of surgical specimens was pCR (pathologic complete response, no viable tumor cells) or MPR (Major pathologic response, residual viable tumor cells≤10%).\n3. Negative surgical margin.\n4. No extranodal extension.\n5. Aged ≥ 18 years and ≤ 70 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n7. Life expectancy of more than 6 months.\n8. Adequate organ function, based on meeting all of the following criteria (no blood components and cytologic growth factors were received within 14 days prior to the test):\n\n   1. Hemoglobin ≥ 75 g\u002FL; absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; and platelet count ≥ 100 × 10\\^9\u002FL;\n   2. Serum albumin ≥ 25 g\u002FL;\n   3. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN;\n   4. Serum creatinine ≤ 1.5 × ULN;\n   5. Activated partial clotting enzyme time and international standardized ratio (INR) ≤ 1.5 × ULN (Patients on stable doses of anticoagulant therapy such as low molecular weight heparin or warfarin with INR within the expected treatment range of anticoagulants can be screened ).\n9. Women of childbearing age should agree to the use of contraception (e.g., intrauterine devices, birth control pills, or condoms) during treatment and for 3 months thereafter.\n10. The regimen of neoadjuvant therapy can be determined by the clinician.\n11. Subjects voluntarily join the study and sign an informed consent form, with good compliance.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. A history of other malignant tumors within the previous 5 years or at the time of enrollment, except for cured skin basal cell carcinoma and cervical in situ cancer, as well as thyroid papilloma.\n3. Neoadjuvant therapy or radical surgery was not completed.\n4. Recurrence or distant metastasis occurred before postoperative radiotherapy.\n5. There are contraindications for radiotherapy, chemotherapy, immunotherapy and targeted therapy.\n6. Uncontrolled cardiac clinical symptoms or diseases.\n7. Serious infections.\n8. A history of immunodeficiency, including HIV-positive status or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and bone marrow transplantation.\n9. Patients with active tuberculosis infection found by history or CT examination, or patients with active tuberculosis infection history within 1 year prior to enrollment, or patients with active tuberculosis infection history before 1 year without formal treatment.\n10. Active hepatitis B (HBV DNA ≥ 2,000 IU\u002FmL or 10,000 copies\u002FmL) or hepatitis C (positive HCV antibody test and HCV RNA above the lower limit of detection).\n11. Known history of psychotropic drug abuse, alcoholism and drug use.\n12. Not suitable for inclusion, as judged by the investigator.","70 Years",{"count":146,"type":22},23,[148],"NA","This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of de-escalation of postoperative radiotherapy in locally advanced head and neck squamous cell carcinoma with pathological complete response\u002Fmajor pathological response to neoadjuvant therapy. The eligible patients are scheduled to administered postoperative radiotherapy, PTV 50Gy\u002F25F, instead of the standard dose of 60Gy. The overall primary study hypothesis is that reducing the dose of postoperative radiotherapy in the specific population does not affect DFS but significantly reduces treatment related adverse events.",[151],"Head and Neck Squamous Cell Carcinoma",[153,154],"pathological complete response","major pathological response","2023-05-03",{"date":157,"type":41},"2023-05-11",{"date":159,"type":41},"2023-04-10",{"date":161,"type":22},"2027-04-09",{"name":47,"class":48},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":189},"100465638","phase-2-the-efficacy-and-safety-of-neoadjuvant-low-dose-radiotherapy-combined-with-chemoimmunotherapy-in-locally-advanced-hnscc-100465638","NCT05343325","The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC","Neoadjuvant Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoRTPC02): an Open Label, Single-arm, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Untreated, histologically confirmed head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx or larynx), staging T3-4N0M0 or T1-4N1-3M0, III-IVB, according to the eighth edition of the AJCC staging system;\n2. Eligible for radical surgery, as judged by surgeons.\n3. Aged ≥ 18 years and ≤ 70 years.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n5. Life expectancy of more than 6 months.\n6. At least one measurable lesion according to RECIST 1.1.\n7. Adequate organ function, based on meeting all of the following criteria (no blood components and cytologic growth factors were received within 14 days prior to the test):\n\n   1. Hemoglobin ≥ 90 g\u002FL; absolute neutrophil count ≥ 1.5 × 109\u002FL; and platelet count ≥ 100 × 109\u002FL;\n   2. Serum albumin ≥ 28 g\u002FL;\n   3. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN;\n   4. Serum creatinine ≤ 1.5 × ULN and creatinine clearance rate ≥ 50 mL\u002Fmin;\n   5. Activated partial clotting enzyme time and international standardized ratio (INR) ≤ 1.5 × ULN (Patients on stable doses of anticoagulant therapy such as low molecular weight heparin or warfarin with INR within the expected treatment range of anticoagulants can be screened ).\n\n      43\u002F5000\n   6. Thyroid Stimulating Hormone (TSH) ≤ULN; If abnormal, T3 and T4 levels should be examined, and patients with normal T3 and T4 levels can be screened.\n8. Women of childbearing age should agree to the use of contraception (e.g., intrauterine devices, birth control pills, or condoms) during drug administration and for 3 months thereafter.\n9. Subjects voluntarily join the study and sign an informed consent form, with good compliance.\n\nExclusion Criteria (Patients will be excluded if any of the following criteria is met):\n\n1. Pregnant or lactating women.\n2. A history of allergies to PD-1 inhibitors or any of albumin-bound paclitaxel or cisplatin.\n3. A history of other malignant tumors within the previous 5 years or at the time of enrollment, except for cured skin basal cell carcinoma and cervical in situ cancer, as well as thyroid papilloma.\n4. Uncontrolled cardiac clinical symptoms or diseases, such as :(1) NYHA class II or higher heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, and (4) patients with clinically significant ventricular or ventricular arrhythmias requiring intervention.\n5. Have received any of the following treatments:\n\n   1. Any research drug received prior to the first dose of the current research drug.\n   2. Joined another clinical study at the same time, unless it is an observational (noninterventional) clinical study or an intervention during a follow-up.\n   3. Needed systemic treatment with corticosteroids (more than 10 mg of prednisone or equivalent per day) or other immunosuppressants within 2 weeks prior to the first dose of the study drug, except for the use of corticosteroids for local inflammation and prevention of allergies or nausea and vomiting. In the absence of active autoimmune diseases, inhalation or partial use of steroids and adrenal corticosteroid replacements at doses greater than 10 mg per day of fentanyl equivalent is permitted.\n   4. Live vaccines were administered within 4 weeks prior to the first administration of research drugs.\n   5. Major surgery or severe trauma within four weeks of initial use of the study drug.\n6. Serious infections (greater than grade 2 according to the Common Terminology Criteria for Adverse Events), such as severe pneumonia, bacteremia, and infection comorbidities, which required hospitalization, occurred within 4 weeks prior to the first dose of the study drug; baseline chest imaging examinations indicate the presence of active lung inflammation or symptoms and signs of infection within 2 weeks prior to the first dose of the study drug or indicate the need for oral or intravenous antibiotic treatment (excluding the use of preventive antibiotics).\n7. A history of active autoimmune diseases and syndromes (including, but not limited to, interstitial pneumonia, colitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, and hypothyroidism). Patients with vitiligo or cured childhood asthma\u002Fallergies that do not require any intervention in adulthood are not excluded.\n8. A history of immunodeficiency, including HIV-positive status or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and bone marrow transplantation.\n9. Patients with active tuberculosis infection found by history or CT examination, or patients with active tuberculosis infection history within 1 year prior to enrollment, or patients with active tuberculosis infection history before 1 year without formal treatment.\n10. Active hepatitis B (HBV DNA ≥ 2,000 IU\u002FmL or 10,000 copies\u002FmL) or hepatitis C (positive HCV antibody test and HCV RNA above the lower limit of detection).\n11. Known history of psychotropic drug abuse, alcoholism and drug use.\n12. Not suitable for inclusion, as judged by the researcher.",{"count":171,"type":22},25,[106],"This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell carcinoma. The eligible patients are scheduled to administered neoadjuvant low-dose radiotherapy, tislelizumab, combined with albumin-bound paclitaxel and cisplatin for two cycles. Radical resection will be performed in 3-4 weeks after two cycles of neoadjuvant therapy. The overall primary study hypothesis is that the novel neoadjuvant combination regime improves the pathological complete response (pCR) rate, with tolerable side effects.",[151,175],"Neoadjuvant Treatment",[177,178,179,180],"locally advanced HNSCC","neoadjuvant treatment","low-dose radiotherapy","pathological response rates","2022-12-26",{"date":183,"type":41},"2022-12-29",{"date":185,"type":41},"2022-03-09",{"date":187,"type":22},"2027-03-31",{"name":47,"class":48},2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":49},"100461556","phase-2-radiotherapy-combined-with-pd-1-monoclonal-antibody-and-capecitabine-in-the-treatment-of-nasopharyngeal-carcinoma-100461556","NCT05290194","Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma","Multi-target Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine Maintenance Therapy Treating Oligometastatic Nasopharyngeal Carcinoma: a Single-arm, Multicenter, Prospective, Open-label Phase II Clinical Trial","Inclusion Criteria:\n\n1. The patient was histologically or cytologically diagnosed with nasopharyngeal carcinoma;\n2. The patient was newly diagnosed with metastatic nasopharyngeal carcinoma (AJCC eighth edition), and after 4-6 cycles of gemcitabine plus cisplatin combined with PD-1 monoclonal antibody regimen, the efficacy reached more than stable disease;\n3. Except for the primary tumor and cervical lymph node metastasis, less than 5 distant organ metastases, and were suitable for SBRT radiotherapy;\n4. ECOG PS score 0-2 points;\n5. Aged 18-70 years old;\n6. Major organ function met the following criteria (14 do not allow the use of any blood components and cell growth factor):\n\n   1. Neutrophil ANC ≥ 2.0 × 10\\^9\u002FL; platelet count PLT ≥ 100 × 10\\^9\u002FL; hemoglobin HB ≥ 90 g\u002FL;\n   2. Serum albumin ≥ 28 g\u002FL;\n   3. Alanine aminotransferase ALT, aspartate aminotransferase AST ≤ 2.5 × ULN; if there is liver metastasis, ALT and AST ≤ 5 × ULN;\n   4. Serum creatinine ≤ 1.5 × ULN, Or creatinine clearance ≥ 60 mL\u002Fmin;\n   5. INR ≤ 1.5 × ULN, and APTT ≤ 1.5 × ULN;\n7. Life expectancy ≥ 12 weeks;\n8. The subject who voluntarily joins the study, sign informed consent, and coordinates with follow-up.\n\nExclusion Criteria:\n\n1. Recurrent and metastatic nasopharyngeal carcinoma after initial treatment;\n2. Patients received previous treatment of primary lesion or metastasis except for the standard first-line regimen (gemcitabine plus cisplatin combined with PD-1 monoclonal antibody regimen), including induction chemotherapy, adjuvant chemotherapy, concurrent chemoradiotherapy, surgery and other treatments;\n3. Central nervous system metastastic (confirmed or suspected);\n4. Allergy to PD-1 monoclonal antibody or other PD-1 monoantibody; intolerance or allergy to capecitabine; suffering any disease or extrinsic factors affecting oral drugs;\n5. Uncontrolled cardiac clinical symptoms or diseases, such as: ① heart failure of NYHA Grade II or higher ; ② unstable angina pectoris; ③ suffering myocardial infarction within 1 year; ④ patients with supraventricular or arrhythmia requiring clinical intervention;\n6. Severe infection (CTCAE 5.0 ≥ 2) 4 weeks before the first use of study drugs, such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; baseline chest imaging examination suggests the presence of active pulmonary inflammation; symptoms and signs of infection or the need for oral or intravenous antibiotics (excluding the prophylactic use of antibiotics) 2 weeks before the first use of the study drug;\n7. History of other malignancies within 5 years or at the time,but except for cured cutaneous basal cell carcinoma and cervical carcinoma in situ, breast carcinoma in situ, superficial bladder tumors (Ta, Tis and T1) and papillary thyroid cancer as well as other cancers treated more than 3 years before the start of the study;\n8. Any of the following conditions is met:\n\n   1. Received any investigational drug before the first use of the study drug;\n   2. Participated in another clinical study at the same time, unless it is an observational (non-interventional) clinical study or interventional clinical study at the follow-up time;\n   3. Required systemic treatments with corticosteroids (the dose higher than the equivalent dose of 10 mg prednisone per day) or other immunosuppressive agents 2 weeks before the first use of the study drug, except for local inflammation and prevention of allergy and nausea and vomiting. In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticotropic hormone replacement at doses greater than 10 mg daily in prednisone efficacy dose are allowed;\n   4. Received anti-tumor vaccines or vaccinated live vaccines 4 weeks before the first dose of study drug;\n   5. Underwent excessive surgery or severe trauma 4 weeks before the first use of study drug;\n9. Patients had active autoimmune diseases and a history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases and syndromes) in the past 2 years; patients who did not require any intervention after adulthood are allowed;\n10. History of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or history of organ transplantation and bone marrow transplantation;\n11. Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or with a history of active pulmonary tuberculosis infection 1 year ago but without regular treatment;\n12. Patients with active hepatitis (HBV ≥ 2000 IU\u002Fml or HBV DNA ≥ 10000\u002Fml), or hepatitis C (hepatitis C antibody positive, and HCV-RNA ≥ 1000\u002Fml);\n13. Patients with coagulation abnormalities (PT \\> 16s, APTT \\> 43s, TT \\> 21s, Fbg \\\u003C 2 g\u002FL), bleeding tendency or receiving thrombolytic or anticoagulant therapy; or patients with previous severe bleeding (bleeding \\> 30ml within 3 months), hemoptysis (bleeding \\> 5ml within 4 weeks) within 12 months due to thromboembolic events (including stroke events and\u002For transient ischemic attack);\n14. Uncontrolled hypertension (systolic blood pressure \\> 140 mmHg, or diastolic blood pressure \\> 90 mmHg); coronary heart disease, arrhythmia ≥ grade II (including QTc prolongation, male \\> 450 ms, female \\> 470 ms) and heart failure;\n15. Urine protein ≥ + +, or 24 hour urine protein ≥ 1.0 g;\n16. Current diarrhea-related diseases (e.g., ulcerative colitis, Crohn's disease, chronic diarrhea, etc.);\n17. Known history of psychotropic drug abuse, alcoholism and drug abuse; or current history of antiepileptic drug use;\n18. Pregnant or lactating;\n19. Patients considered unsuitable for inclusion by the investigator as assessed by the investigator.",{"count":21,"type":22},[106],"This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal carcinoma, the main purpose of which is to evaluate the efficacy of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy regimen in treating oligometastatic nasopharyngeal carcinoma.",[201,202,203,204],"Radiotherapy","PD-1 Inhibitor","Capecitabine","Nasopharyngeal Carcinoma","2022-04-13",{"date":207,"type":41},"2022-04-14",{"date":209,"type":41},"2022-03-28",{"date":211,"type":22},"2027-01-01",{"name":47,"class":48},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100438519","dachaihu-decoction-compound-and-rhubarb-single-medicine-in-the-treatment-of-acute-pancreatitis-100438519","NCT04990336","Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis","Comparison of Clinical Efficacy of Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis","Inclusion Criteria:\n\n* Age from 18 to 65 years old\n* Meet the diagnostic criteria of western medicine for acute pancreatitis, within 48 hours of onset\n* Consent of the subjects, who sign the informed consent form\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding\n* Acute abdomen such as organic intestinal obstruction, gastrointestinal perforation, purulent cholangitis, etc.\n* Patients with a history of severe heart, liver, kidney and other important organ diseases\n* Patients with mental illness and malignant tumors\n* People who have allergies, or are allergic to a certain drug ingredient",{"count":221,"type":22},306,[148],"A large number of clinical studies have shown that oral administration, external application or enema of Chinese medicine can promote the recovery of gastrointestinal function and the absorption of pancreatic inflammation. The aims of the study is to explore the application of Dachaihu Decoction Compound (DDC)and Rhubarb Single Medicine (RSM) in the Treatment of Acute Pancreatitis.",[225],"Acute Pancreatitis",[225,227,228],"Dachaihu Decoction Compound","Rhubarb Single Medicine","2022-03-22",{"date":231,"type":41},"2022-03-24",{"date":133,"type":22},{"date":234,"type":22},"2029-07-31",{"name":47,"class":48},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":49},"100447400","clinical-study-on-the-efficacy-of-single-port-inflatable-mediastinoscopy-combined-with-laparoscopic-assisted-small-incision-surgery-and-thoracoscopy-combined-with-laparoscopic-surgery-for-radical-esophagectomy-100447400","NCT05105945","Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy","A Randomized, Controlled, Multi-center Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 75 years old, no gender limit;\n2. Patients who are diagnosed as esophageal malignant tumor by cytology or histology, and agree to undergo surgical treatment;\n3. The preoperative clinical tumor staging is T1-2N0-1M0 patients; or T3N1-2M0 patients undergo neoadjuvant treatment (neoadjuvant chemotherapy, neoadjuvant chemoradiation, neoadjuvant radiotherapy, neoadjuvant chemotherapy and immunotherapy, neoadjuvant radiotherapy and immunotherapy After treatment), assess the tumor to achieve partial response (PR) and surgical resection is feasible;\n4. The tumor is located in the thoracic esophagus;\n5. The tumor has not invaded the surrounding vital organs and has metastasized far away;\n6. The function of major organs is basically normal: general anesthesia is acceptable for lung function; NYHA grade of heart function is 0\\~1;\n7. Voluntarily sign an informed consent form before the study. The patient and\u002For his legal representative have the ability to fully understand the content, process and possible adverse reactions of the experiment, and enable the patient to comply with the visits stipulated in the plan;\n\nExclusion Criteria:\n\n1. People who suffer from other malignant tumors at the same time;\n2. Patients with a history of esophagus or gastrectomy;\n3. Patients with a history of mediastinal surgery or extensive abdominal cavity adhesion;\n4. Patients with basic diseases such as cardiovascular and cerebrovascular diseases;\n5. People suffering from mental, mental or neurological diseases;\n6. Patients with cachexia and severe malnutrition who cannot tolerate surgery;\n7. Recent recurrence of gastric ulcer, history of gastric bleeding and other serious underlying diseases;\n8. Patients with surgical contraindications such as blood coagulation dysfunction, HIV antibody positive, and poorly controlled clinically severe infections;\n9. Patients with other comorbid diseases (such as liver and kidney function abnormalities, etc.) or concomitant medications, which may have an impact on the results of this study based on the judgment of the investigator.\n10. Patients who have participated in other clinical studies;\n11. Others judged by the investigator to be unsuitable to participate in this clinical trial.","75 Years",{"count":245,"type":22},1164,[148],"We previously developed a novel non-trans thoracic esophagectomy, the single-port inflatable mediastinoscopy combined with laparoscopy for the radical esophagectomy of esophageal cancer.This study is evaluating the feasibility and safety of radical resection of single-port inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, as well as the clinical value of the radical resection of single-port inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma as a new minimally invasive operation for esophageal carcinoma.",[249],"Esophageal Cancer",[251],"Minimally invasive surgery","2021-10-25",{"date":254,"type":41},"2021-11-03",{"date":256,"type":22},"2021-11-11",{"date":258,"type":22},"2028-12-28",{"name":47,"class":48},""]